Do firms respond to peer disclosures? Evidence from clinical trial disclosures
We examine whether a firm’s decision to disclose non-financial proprietary information depends on peer disclosures of similar information. Using a sample of 5,035 unique clinical trials by U.S. pharmaceutical firms over the 2007-2014 period, we find that the firm is less likely to disclose its own c...
محفوظ في:
المؤلفون الرئيسيون: | CAPKUN, Vedran, LOU, Yun, OTTO, Clemens A., WANG, Yin |
---|---|
التنسيق: | text |
اللغة: | English |
منشور في: |
Institutional Knowledge at Singapore Management University
2021
|
الموضوعات: | |
الوصول للمادة أونلاين: | https://ink.library.smu.edu.sg/soa_research/1789 https://ink.library.smu.edu.sg/context/soa_research/article/2816/viewcontent/SSRN_id3344942otto.pdf |
الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Do firms respond to peer disclosures? Evidence from disclosures of clinical trial results
بواسطة: CAPKUN, Vedran, وآخرون
منشور في: (2023) -
Consequences of disclosing clinical trial results: Evidence from the food and drug administration amendments act
بواسطة: BORVEAU, Thomas, وآخرون
منشور في: (2020) -
The effect of mandatory ESG disclosure on firms’ going-private decisions
بواسطة: HUANG, Ying-Chi
منشور في: (2024) -
Regulatory interventions in response to noncompliance with mandatory derivatives disclosure rules
بواسطة: BHATTACHARYA, Neil, وآخرون
منشور في: (2022) -
Trade secrets law and corporate disclosure: Causal evidence on the proprietary cost hypothesis
بواسطة: LI, Yinghua, وآخرون
منشور في: (2018)